Clinical Trials Logo

Filter by:
NCT ID: NCT01966341 Withdrawn - Clinical trials for Irritable Bowel Syndrome (IBS)

Collaborative Cognitive Behavioral Therapy / Hypnotherapy for Treatment of Pediatric Functional Gastrointestinal Disease

CAPP
Start date: April 2014
Phase: N/A
Study type: Interventional

This program has been created to help patients with irritable bowel syndrome manage their symptoms and increase their functioning by using cognitive therapy skills and hypnosis.

NCT ID: NCT01969682 Withdrawn - Clinical trials for Non-Hodgkin's Lymphoma

A Study to Assess the Effect of Rifampin on the Metabolism of ABT-199

Start date: April 2014
Phase: Phase 1
Study type: Interventional

This is an open-label multicenter, study to assess the pharmacokinetic interaction of rifampin with ABT-199 in up to 12 subjects with relapsed or refractory non-Hodgkin's lymphoma.

NCT ID: NCT01971541 Withdrawn - Depression Clinical Trials

Groups for Regaining Our Wellbeing (GROW)

GROW
Start date: April 2014
Phase: Phase 2/Phase 3
Study type: Interventional

The proposed study is a randomized, controlled trial that will assess whether two group interventions for PTSD - Mindfulness-Based Stress Reduction (MBSR) and Cognitive Processing Therapy-Cognitive only (CPT-C) result in similar improvements in PTSD symptoms and health-related quality of life (QOL). One hundred fifty-two Veterans with PTSD will be randomized to MBSR (n = 76) or CPT-C (n = 76). Comprehensive assessments will take place post-treatment and 3 months later.

NCT ID: NCT01973517 Withdrawn - Multiple Sclerosis Clinical Trials

High-Field MRI Iron-Based Contrast-Enhanced Characterization of Multiple Sclerosis and Demyelinating Diseases

Start date: April 2014
Phase:
Study type: Observational

Feraheme (ferumoxytol) is FDA-approved for iron supplementation and is composed of iron oxide nanoparticles classified among the ultra-small superparamagnetic iron oxides (USPIO). In this project we hypothesize that Feraheme could become a sensitive and specific marker of active inflammation in multiple sclerosis. We will explore this hypothesis taking advantage of ultra high field strength (7T) MRI to further increase the effectiveness of the contrast agent Feraheme at revealing inflammatory activity.

NCT ID: NCT01977586 Withdrawn - Clinical trials for Metastatic Renal Cell Carcinoma

Functional Imaging in the Assessment of mRCC Response to Sunitinib

Start date: April 2014
Phase: N/A
Study type: Interventional

The aim of this study is to assess whether functional magnetic resonance imaging (MRI) techniques are able to detect which patients with metastatic renal cell carcinoma will derive benefit from treatment with anti-angiogenic drugs early in their treatment. Early response assessment would allow selection of the most appropriate treatment option for each individual patient.

NCT ID: NCT01986816 Withdrawn - Obesity Clinical Trials

Return on Investment on Lap Gastric Bypass Regarding Quality of Life

ROI-LGBP
Start date: April 2014
Phase:
Study type: Observational

The purpose of this study is to investigate the cost of treatment and adverse efffects therof corresponds to quality of life improvements and expected wheightloss.

NCT ID: NCT01997255 Withdrawn - Clinical trials for Sturge Weber Syndrome

Adjunctive Everolimus (RAD 001) Therapy for Epilepsy in Children With Sturge-Weber Syndrome (SWS)

Start date: April 2014
Phase: Phase 2
Study type: Interventional

Sturge Weber Syndrome (SWS) is a rare disease that affects the patient's brain and causes benign (non-cancerous) tumors to grow in the brain. One of the symptoms of SWS is epilepsy. People with epilepsy have seizures. Some patients may also have eye problems and a red mark on their facial skin. This study is being done to find out if the study drug, everolimus, is safe and has helpful effects in patients with SWS who have seizures and are not responding to their current anti-epileptic medication. The study drug, everolimus (Afinitor®), is supplied by Novartis Pharmaceuticals Corporation.

NCT ID: NCT02029612 Withdrawn - Clinical trials for Tobacco Use Cessation

An Evidence Based Smoking Cessation Program for Persons Living With HIV/AIDS (Project Legacy)

Start date: April 2014
Phase: N/A
Study type: Interventional

The goal of this research study is to compare 2 different phone-based programs for quitting smoking for people with HIV/AIDS.

NCT ID: NCT02031380 Withdrawn - Clinical trials for Glaucoma, Open-Angle [C11.525.381.407]

iDropper Usability in Glaucoma

Start date: April 2014
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the usability of a medication management support system for glaucoma patients self-administering eye drops named iDropper. The iDropper system is a home-based ocular medication management system that reminds, instructs, dispenses, and records eye drop medication usage. The iDropper system will be evaluated among a cohort of glaucoma subjects self-administering eye drops for 4-weeks.

NCT ID: NCT02034097 Withdrawn - Cancer Clinical Trials

A Study to Evaluate Foretinib in Subjects With Non-Small-Cell Lung Cancer

Start date: April 2014
Phase: Phase 2
Study type: Interventional

Foretinib (GSK1363089) is an investigational, oral, multikinase inhibitor involved in invasion, migration, and angiogenesis. This is a phase II, open label, uncontrolled, parallel, multi-cohort, multicenter 2-stage study to assess the safety and efficacy of foretinib and erlotinib combination therapy and foretinib monotherapy in genomic subpopulations of Non-Small-Cell Lung Cancer (NSCLC) subjects.